JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a
clinical-stage pharmaceutical company focused on the development of
oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific
Officer, will deliver a presentation titled, "Oral Insulin for
Diabetes Treatment: Bypassing the Roadblock" at the upcoming BIT'S
5th World Congress of Diabetes-2017 and BIT's 6th World Congress of
Endobolism-2017 in Prague, Czech
Republic.
Presentation Details:
Presenting on Track 1-2: Insulin Action & Secretion and
Insulin Resistance
Date:
July 13, 2017
Location: Vienna House
Diplomat Prague
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the
field of oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's PODTM
technology is based on over 30 years of research by scientists at
Jerusalem's Hadassah Medical
Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801). The Company has
completed multiple Phase II clinical trials of ORMD-0801 under an
Investigational New Drug application with the U.S. Food and Drug
Administration. In addition, Oramed is developing an oral GLP-1
analog capsule (ORMD-0901).
For more information, the content of which is not part of this
press release, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, we are using
forward-looking statements when we discuss revolutionizing the
treatment of diabetes with our products. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Oramed Pharmaceuticals
Josh Hexter
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: josh@oramed.com
View original
content:http://www.prnewswire.com/news-releases/oramed-to-present-at-bits-5th-world-congress-of-diabetes-on-july-13-2017-300486834.html
SOURCE Oramed Pharmaceuticals Inc.